PT  - JOURNAL ARTICLE
AU  - Douglas Ramsay
AU  - I. Craig Carr
AU  - John Pediani
AU  - Juan F. Lopez-Gimenez
AU  - Richard Thurlow
AU  - Mark Fidock
AU  - Graeme Milligan
TI  - High-Affinity Interactions between Human α<sub>1A</sub>-Adrenoceptor C-Terminal Splice Variants Produce Homo- and Heterodimers but Do Not Generate the α<sub>1L</sub>-Adrenoceptor
AID  - 10.1124/mol.66.2.228
DP  - 2004 Aug 01
TA  - Molecular Pharmacology
PG  - 228--239
VI  - 66
IP  - 2
4099  - http://molpharm.aspetjournals.org/content/66/2/228.short
4100  - http://molpharm.aspetjournals.org/content/66/2/228.full
SO  - Mol Pharmacol2004 Aug 01; 66
AB  - Using combinations of bioluminescence resonance energy transfer, time-resolved fluorescence resonance energy transfer and the functional complementation of pairs of inactive receptor-G protein fusion proteins, the human α1A-1-adrenoceptor was shown to form homodimeric/oligomeric complexes when expressed in human embryonic kidney (HEK) 293 cells. Saturation bioluminescence resonance energy transfer studies indicated the α1A-1-adrenoceptor homodimer interactions to be high affinity and some 75 times greater than interactions between the α1A-1-adrenoceptor and the δ opioid peptide receptor. Only a fraction of the α1A-1-adrenoceptors was at the plasma membrane of HEK293 cells at steady state. However, dimers of α1A-1-adrenoceptors were also present in intracellular membranes, and the dimer status of those delivered to the cell surface was unaffected by the presence of agonist. Splice variation can generate at least three forms of the human α1A-1-adrenoceptor with differences limited to the C-terminal tail. Each of the α1A-1, α1A-2a, and α1A-3a-adrenoceptor splice variants formed homodimers/oligomers, and all combinations of these splice variants were able to generate heterodimeric/oligomeric interactions. Despite the coexpression of these splice variants in human tissues that possess the pharmacologically defined α1L-adrenoceptor binding site, coexpression of any pair in HEK293 cells failed to generate ligand binding characteristic of the α1L-adrenoceptor.